FOCUSING ON THE NEXT GENERATION OF THERAPEUTICS

Our technologies are based on cutting-edge scientific research from top tier universities.

ABOUT HOTH THERAPEUTICS

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).

BIOLEXA PLATFORM OVERVIEW

BioLexa platform technology is a patented topical agent that combines a chelating agent with an antibiotic in a proprietary formula, to fight bacterial infections across multiple platforms. The current formulation has applicability in the areas of:

  • Eczema
  • Aesthetic dermatology
  • Surgical site infections
  • Chronic wound care
  • Chronic diabetic wound care

INVESTORS

Hoth Therapeutics seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes upcoming events, presentations and financial documents.

SCIENTIFIC ADVISORY BOARD

View our Scientific Advisory Board and their bios here.

BIOLEXA OPPORTUNITY

Applications for the BioLexa platform from Hoth Therapeutics